Editas Medicine
EDIT
214 hedge funds and large institutions have $386M invested in Editas Medicine in 2026 Q2 according to their latest regulatory filings, with 34 funds opening new positions, 75 increasing their positions, 42 reducing their positions, and 24 closing their positions.
203% more capital invested
Capital invested by funds: $128M → $386M (+$259M)
131% more call options, than puts
Call options by funds: $4.28M | Put options by funds: $1.85M
79% more repeat investments, than reductions
Existing positions increased: 75 | Existing positions reduced: 42
68.87% more ownership
Funds ownership: 52.96% → 121.83% (+69%)
42% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 24
3% more funds holding
Funds holding: 208 → 214 (+6)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
TCG Crossover Management
Palo Alto,
California
|
+$32.5M |
| 2 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$26M |
| 3 |
CC
Commodore Capital
New York
|
+$26M |
| 4 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$26M |
| 5 |
PBA
Paradigm Biocapital Advisors
New York
|
+$16.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$4.39M |
| 2 |
Nuveen
Charlotte,
North Carolina
|
-$4.26M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$1.31M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$1.3M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$1.22M |
EDIT Hedge Fund Activity: Q2 2026 in Review
214 of the 8,287 institutional investors tracked by Wall St. Rank reported a position in Editas Medicine (EDIT) for Q2 2026, worth a combined $386M — up 203% from $128M a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new EDIT positions and 24 closed out — a net gain of 10 holders — while 75 added to existing stakes and 42 trimmed.
The largest buyer was TCG Crossover Management, opening a new position worth an estimated $32.5M. The largest seller was Renaissance Technologies, cutting an estimated $4.39M.
- 214 institutional investors held Editas Medicine (EDIT) as of Q2 2026, up from 208 in Q1 2026.
- Funds reported $386M of Editas Medicine stock for Q2 2026, up 203% quarter-over-quarter.
- 34 funds opened new Editas Medicine positions in Q2 2026 and 24 closed out, a net change of +10 holders.
- The largest Editas Medicine buyer in Q2 2026 was TCG Crossover Management, an estimated $32.5M added.
- The largest Editas Medicine seller in Q2 2026 was Renaissance Technologies, an estimated $4.39M sold.
Based on aggregated 13F filings for Q2 2026.